Advertisement
Canada markets close in 25 minutes
  • S&P/TSX

    22,294.58
    +35.11 (+0.16%)
     
  • S&P 500

    5,185.15
    +4.41 (+0.09%)
     
  • DOW

    38,877.37
    +25.10 (+0.06%)
     
  • CAD/USD

    0.7284
    -0.0037 (-0.51%)
     
  • CRUDE OIL

    78.50
    +0.02 (+0.03%)
     
  • Bitcoin CAD

    86,664.23
    +348.27 (+0.40%)
     
  • CMC Crypto 200

    1,307.79
    -57.33 (-4.20%)
     
  • GOLD FUTURES

    2,320.30
    -10.90 (-0.47%)
     
  • RUSSELL 2000

    2,068.77
    +8.10 (+0.39%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • NASDAQ

    16,328.69
    -20.55 (-0.13%)
     
  • VOLATILITY

    13.35
    -0.14 (-1.04%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6771
    -0.0021 (-0.31%)
     

Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed

Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed

Biogen and Ionis are unlikely to see a competitor to Spinraza in 2018, as rival AveXis faces a significant delay for its competing drug.